Viridian Therapeutics (VRDN) Set to Announce Quarterly Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is expected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.02) per share and revenue of $4.72 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. On average, analysts expect Viridian Therapeutics to post ($4.07) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $24.09 on Wednesday. The business’s 50-day moving average is $21.65 and its two-hundred day moving average is $22.05. The firm has a market capitalization of $2.73 billion, a PE ratio of -7.15 and a beta of 1.11. Viridian Therapeutics has a 12 month low of $13.18 and a 12 month high of $34.29.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total value of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on VRDN shares. Truist Financial upped their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. Royal Bank Of Canada boosted their price target on Viridian Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $39.00 price target on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.92.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.